The global healthcare third-party logistics market size is expected to reach USD 368.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 7.6% from 2023 to 2030. Some factors driving the growth of this market include technological advancements that help in developing new technologies to engage with consumers, reduction of operational costs through their use, and their assistance in expanding a business into emerging countries and new markets.
The COVID-19 pandemic significantly impacted the supply chain market and the way it is managed. However, the third-party logistics industry showed steady growth amid this pandemic. This is because the sector matched the rising demand with reliable manufacturers worldwide. In addition to the basic storage and transportation services during the pandemic, they also provided procurement assistance to relatively small retailers. There has also been an increase in healthcare companies partnering with third-party logistics providers to operate in a growing and changing set of regulatory requirements that vary by product classification, region, and state.
Healthcare third-party logistics (3PL) companies help in complying with these regulations without disturbing the time duration, efficiency, and cost-effectiveness. They also help in streamlining and simplifying the regulatory compliance process. Moreover, several service providers are focusing on expanding their logistic service portfolio via merger & acquisition strategies. For instance, in August 2022, UPS announced the imminent acquisition of Bomi Group, a multinational, industry-leading healthcare logistics provider. The acquisition would add temperature-controlled facilities in 14 countries to the UPS Healthcare network in Latin America and Europe.
Request a free sample copy or view report summary: Healthcare Third-party Logistics Market Report
The industry segment is further classified into biopharmaceutical, pharmaceutical, and medical devices, with the biopharmaceutical segment accounting for the largest revenue share of 62.0% in 2022
The cold chain logistics segment is anticipated to advance at the fastest CAGR of 10.5% during the forecast period. This is due to the rising global demand for biologics, which is a novel class of pharmaceutical
North America dominated the global market with the largest revenue share of 42.6% in 2022, owing to the presence of several major industry players in the region, as well as the strong growth in pharmaceutical and biopharmaceutical exports and imports
The warehousing and storage segment dominated the global market with a revenue share of 43.3% in 2022, owing to the increasing demand for biologics that require controlled temperature storage and warehousing facilities
Grand View Research has segmented the global healthcare third-party logistics market based on industry, supply chain, service type, and region:
Healthcare Third-party Logistics Industry Outlook (Revenue, USD Billion, 2018 - 2030)
Biopharmaceutical
Vaccines
Plasma Derived Products
Others
Medical Device
Class I
Class II
Class III
Pharmaceutical
Healthcare Third-party Logistics Service Type Outlook (Revenue, USD Billion, 2018 - 2030)
Transportation
Air Freight
Sea Freight
Overland Transportation
Warehousing and Storage
Others
Healthcare Third-party Logistics Supply Chain Outlook (Revenue, USD Billion, 2018 - 2030)
Cold Chain
Non-Cold Chain
Healthcare Third-party Logistics Regional Outlook (Revenue, USD Billion, 2018 - 2030)
North America
U.S.
Canada
Europe
U.K.
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players in the Healthcare Third-party Logistics Market
Cardinal Health
DHL Group
Agility
SF Express
Kinesis Medical B.V.
United Parcel Service of America, Inc.
Barrett Distribution
AmerisourceBergen Corporation
DB Schenker
FedEx
KUEHNE + NAGEL
Kerry Logistics Network Ltd.
Freight Logistics Solutions
"The quality of research they have done for us has been excellent..."